NCT05307133Completed
Oxytocin and Sleeve Gastrectomy
Oxytocin Serum Variation Following Laparoscopic Sleeve Gastrectomy in Morbidly Obese Women
Source: ClinicalTrials.gov · Last updated 5 Mar 2025
Brief summary (registry, in English)
Morbid obesity has become a common condition and there is no effective drug that is able to induce a sustained weight loss. Currently bariatric surgery remains the only effective means that is able to lead to long term sustained weight loss. Oxytocin is a hormone secreted by the hypophysis that regulates negatively the adipogenesis and positively the osteogenesis. Oxytocin also regulates appetite and its role in weight loss in humans has not been investigated so far. The aim of the present study is to elucidate whether plasma levels of oxytocin and sleeve gastrectomy induced weight loss are correlated in pre-menopausal morbidly obese women.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 24 Mar 2022
- Start date
- 24 Nov 2022
- Primary completion date
- 4 Mar 2024
- Lead sponsor
- Centre Hospitalier Universitaire de Nice
- Diseases
- Obesity
- NCT number
- NCT05307133
What you commit to
- Study type: Interventional
- Participants enrolled: 20
- From 24 Nov 2022 to the primary completion date, 4 Mar 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- any other bariatric procedure that sleeve gastrectomy, history of any other bariatric procedure,
Age
- age less than 18 years under, under guardianship
Other
- Post-menopausal women,
- pregnancy,
- Patients undergoing any other procedure that the planned sleeve gastrectomy or undergoing a second bariatric procedure for a complications during the 6 months follow-up.
Who the study is looking for
- Women aged 18-65, pre-menopausal,
- able to read and understand the written informed consent,
- with a BMI \> 40 or 35
- with at least one obesity linked comorbidity among blood hypertension,
- type 2 diabetes,
- sleep apnea syndrome,
- invalidating arthritis,
- indication for sleeve gastrectomy
- accepted by the multidisciplinary committee and the CPAM (local health care system agency),
- affiliation to the Fre,nch health care system,
- signature of the informed consent.
Age in the registry: 18 years to 65 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de Nice Coordinator of this site? Confirm its status | Nice | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.